Skip to main content
DR REDDYS LABORATORIES LTD logo

DR REDDYS LABORATORIES LTD — Investor Relations & Filings

Ticker · RDY ISIN · US2561352038 LEI · 335800OVDPY3DVZR2798 BSE.NS Manufacturing
Open in API
Filings indexed 2,316 across all filing types
Latest filing 2025-11-27 Regulatory Filings
Country IN India
Listing BSE.NS RDY

About DR REDDYS LABORATORIES LTD

https://www.drreddys.com/

Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company focused on providing affordable and innovative medicines. The company's core activities include the development, manufacturing, and marketing of a broad portfolio of products. This portfolio encompasses Active Pharmaceutical Ingredients (APIs), generic and branded-generic formulations, over-the-counter (OTC) products, and biologics. In addition to its significant presence in the generics market, the company invests in the research and development of novel molecules and proprietary products, with a focus on therapeutic areas such as dermatology and neurology. Dr. Reddy's is also committed to sustainable operations, actively working to reduce its environmental footprint through initiatives in water conservation, waste reduction, and decarbonisation.

Recent filings

Filing Released Lang Actions
FORM 6-K
Regulatory Filings
2025-11-27 English
FORM 6-K
Regulatory Filings
2025-11-27 English
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
Regulatory Filings Classification · 95% confidence The document is a formal disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, informing stock exchanges about a tax demand order received by a subsidiary. It details the nature of the order, the authority involved, and the financial impact, but does not contain financial statements or detailed financial analysis. The document is a regulatory announcement about a legal/tax matter rather than a full report or financial filing. It is short (2666 characters) and serves as an official notification to the exchanges. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-11-26 English
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
Regulatory Filings Classification · 95% confidence The document is a formal disclosure letter addressed to stock exchanges regarding a regulatory matter involving a tax demand and penalty imposed on a subsidiary company. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events. The document does not contain financial statements, detailed financial analysis, or management discussion. It is a regulatory announcement informing stakeholders about a legal/tax issue and its potential impact. The document length is 2631 characters, which is relatively short and consistent with a regulatory announcement rather than a full report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-11-26 English
FORM 6-K
Regulatory Filings
2025-11-25 English
Announcement under Regulation 30 of SEBI (LODR) Regulations, 2015 - Press Release
Regulatory Filings Classification · 95% confidence The document is a press release dated November 24, 2025, from Dr. Reddy's Laboratories announcing the European Commission approval for AVT03, a biosimilar drug. It is addressed to stock exchanges and references a disclosure under SEBI regulations. The content focuses on the approval news, licensing agreements, product details, and company background. There are no financial statements, detailed financial performance data, or management discussion of results. The document is informational and serves as a regulatory disclosure and press release rather than a financial report or detailed investor presentation. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a voting result, board change, or legal proceeding. The document is a regulatory announcement informing the market about a significant corporate event (drug approval). Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements and disclosures that do not fit other categories.
2025-11-24 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.